<prompt> Please answer with one of the option in the bracket. Write reasoning in between . Write answer in between .Q:Background:Beta-blockers reduce mortality in patients who have heart failure reduced ejection fraction and are on background treatment with diuretics and angiotensin-converting enzyme inhibitors. We aimed to compare the effects of carvedilol and metoprolol on clinical outcome.Methods:In a multicenter, double-blind, and randomized parallel group trial, we assigned 1,511 patients with chronic heart failure to treatment with carvedilol target dose 25 mg twice daily and 1,518 to metoprolol metoprolol tartrate, target dose 50 mg twice daily. Patients were required to have chronic heart failure NYHA II-IV, previous admission for a cardiovascular reason, an ejection fraction of less than 0.35, and have been treated optimally with diuretics and angiotensin-converting enzyme inhibitors unless not tolerated. The primary endpoints were all-cause mortality and the composite endpoint of all-cause mortality or all-cause admission. The analysis was done by intention to treat.Findings:The mean study duration was 58 months SD 6. The mean ejection fraction was 0.26 0.07, and the mean age 62 years 11. The all-cause mortality was 34 512 of 1,511 for carvedilol and 40 600 of 1,518 for metoprolol hazard ratio 0.83 95 CI 0.74-0.93, p0.0017. The reduction of all-cause mortality was consistent across predefined subgroups. The incidence of side effects and drug withdrawals did not differ by much between the two study groups.To which of the following patients are the results of this clinical trial applicable?? A: A 62-year-old male with primarily preserved ejection fraction heart failure, B: A 75-year-old female with systolic dysfunction and an EF of 45, C: A 56-year-old male with NYHA class I systolic heart failure, D: A newly diagnosed 66-year-old male who has yet to begin treatment for his NYHA class II left-sided heart failure, E: A 68-year-old male with NYHA class II systolic heart failure and EF 30,  <response>: This is a clinical trial comparing the effects of carvedilol versus metoprolol in patients with chronic heart failure and reduced ejection fraction who are on background treatment with diuretics and ACE inhibitors. The key inclusion criteria were:- Chronic heart failure NYHA class II-IV- Previous admission for cardiovascular reason- Ejection fraction 0.35- On optimal treatment with diuretics and ACE inhibitors The primary endpoints were all-cause mortality and composite of all-cause mortality or hospital admission.The results showed carvedilol reduced all-cause mortality compared to metoprolol. The side effects were similar between groups.To determine which patient the results apply to, we need to consider the inclusion criteria - specifically, patients with chronic systolic heart failure on optimal medical therapy.E: A 68-year-old male with NYHA class II systolic heart failure and EF 30 